Treatment of menorrhagia with mazu

Effect of Mazu Quercusinfectoria in Kasrate Tams A Single Blind Randomize Control Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042871

Enrollment

Registered

2022-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

Intervention1: Mazu: Two capsules each of 500mg BD orally with water will be given from 1st day of menses until bleeding stops for two consecutive cycles Control Intervention1: Tranexamic acid 500mg:

Eligibility

Inclusion criteria

Inclusion criteria: Married women of 18 to 40 years of age Regular menses PBAC score above 100

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Severe anemia and blood dyscrasias Organic pelvic pathology Systemic and metabolic illnesses Recent history of dengue and chicken guinea Women on anticoagulants OCPs and having IUCDs

Design outcomes

Primary

Measure	Time frame
Change in PBAC score Timepoint: Baseline Before and after menses for 3 consecutive cycles	—

Secondary

Measure	Time frame
Change in quality of life SF-12score Change in Hb% Timepoint: Baseline Before and after menses for 3 consecutive cycles	—

Countries

India

Contacts

Public ContactDr Mohd Aqil Quadri

Luqman Unani Medical College Hospital and Research Centre

nikhatinamdar72@gmail.com7795447144

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026